• New Nasodine® Throat Spray product launched in Singapore and Fiji
• Expanded US promotion, broader Singapore pharmacy distribution, and first orders in Fiji
• Real-world user survey data shows high satisfaction with Nasodine Nasal Spray

Firebrick Pharma Ltd reported its business activity update for the quarter ending 31 December 2025, along with its Appendix 4C quarterly cash flow report. Key highlights include the launch of the new Nasodine® Throat Spray product, which received TGA export approval and commenced commercial manufacturing and export to Singapore. The company also outlined plans for expanded US promotion, broader Singapore pharmacy distribution, and the first orders of the Throat Spray in Fiji. Additionally, the company conducted a real-world user survey of Nasodine Nasal Spray, which showed very positive results, with 96% of users rating the product as effective or better and 97% finding it easy to use. Financially, the company reported a 15% increase in December quarter cash sales versus the prior year, while base operating costs fell 15% quarter-on-quarter and 34% year-on-year, positioning the company for a declining cash burn as revenues continue to scale.

The company reported a 15% increase in December quarter cash sales versus the prior year, while base operating costs fell 15% quarter-on-quarter and 34% year-on-year, positioning the company for a declining cash burn as revenues continue to scale.

The company outlined multiple near-term growth catalysts, including expanded US promotion, broader Singapore pharmacy distribution, and the launch of Nasodine Throat Spray in Fiji and other markets in Southeast Asia and the Middle East.